Navigation Links
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
Date:8/8/2014

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at three upcoming investor events. Details of the three events are as follows:

Canaccord 34th Annual Growth Conference
Date: Wednesday August 13th
Location: Boston, MA
Presentation Time: 2:30 pm ET, 11:30 am PT

Guggenheim One on One Day
Date: Tuesday August 19th
Location: San Francisco, CA

The Trout Group Management Roundtable
Date: Thursday August 21th
Location: Bridgehampton, NY

The Canaccord Conference presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, Zalviso, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalvis
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.
2. AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso
3. AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
4. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
5. AcelRx Pharmaceuticals Adds New Board Member
6. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
7. AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
8. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
10. David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
11. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... New Jersey (PRWEB) , ... September 01, 2015 , ... ... one of the 50 Best Companies for Latinas in the LATINA Style 50 Report ... United States. , For 2015, Horizon BCBSNJ climbs from number 24 ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and prevent different malignancies. Some options for cancer treatment are available belonging ... which distinctive approach is necessary for effective treatment. Several molecules have been ...
(Date:9/1/2015)... ... September 01, 2015 , ... As part of its ongoing ... of Minnesota (Blue Cross) has announced Doctor On Demand as the company’s preferred ... On Demand provides immediate access to Board Certified physicians or next-day appointments with ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure ... inside a wound to remove exudates, fluid, and infectious materials to prepare the ... stand-alone devices, disposable devices, and canisters, etc.) is projected to expand continuously through ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... Oct. 5 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... announced underwritten public offering. The Company sold 4,600,000,shares ... in its public offering,resulting in approximately $65.5 million ...
... Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) ... grant to Los Angeles Biomedical Research Institute at Harbor-UCLA ... penile endogenous (adult) stem cells with the company,s drug, ... the drug to provide long-term correction of male erectile ...
... monitoring over whole-brain radiotherapy , MONDAY, Oct. 5 ... learning and memory problems when whole-brain radiation therapy ... researchers have found. , SRS delivers narrowly focused ... The study included 58 patients with one to ...
... warns World Vision , - World Vision to open 13 ... calls on Indonesian government to prioritize its relief efforts to ... schoolchildren in Indonesia,s West Sumatra quake zone were called back ... of children affected by last week,s earthquake remain the disaster,s ...
... ... company, is launching its second "Boost Your Juice Contest" in October, in which healthcare ... win a free Internet marketing campaign worth up to $5,000. , ... Phoenix, AZ (PRWEB) October 5, 2009 ...
... Extent of the Prematurity Crisis Still Unknown, March of Dimes Says ... one million infants die each year because they are born too ... and Regional Toll of Preterm Birth. , The new White ... were born preterm -- defined as birth at less than 37 ...
Cached Medicine News:Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 2Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 3Health News:ESAI provides grant to LA BioMed to investigate long-term correction of erectile dysfunction 2Health News:Focused Radiation Protects Tumor Patients' Brain Function 2Health News:As Schools Reopen in Indonesia, World Vision Says Children's Basic Needs Still Not Being Met 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 3Health News:Global Death Toll: One Million Premature Babies Every Year 2Health News:Global Death Toll: One Million Premature Babies Every Year 3Health News:Global Death Toll: One Million Premature Babies Every Year 4Health News:Global Death Toll: One Million Premature Babies Every Year 5
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: